High Insider Ownership Growth Stocks To Consider In January 2025

In This Article:

As global markets navigate a mixed start to 2025, with U.S. stocks finishing the previous year on a high note despite recent economic concerns, investors are keenly observing companies with strong insider ownership as potential opportunities for growth. In this context, firms where insiders hold significant stakes can be particularly appealing, as their vested interest in the company's success often aligns with shareholder value creation and resilience amid fluctuating market conditions.

Top 10 Growth Companies With High Insider Ownership

Name

Insider Ownership

Earnings Growth

SKS Technologies Group (ASX:SKS)

29.7%

24.8%

Propel Holdings (TSX:PRL)

23.8%

37.6%

CD Projekt (WSE:CDR)

29.7%

27%

Medley (TSE:4480)

34%

31.7%

Pharma Mar (BME:PHM)

11.8%

56.2%

Plenti Group (ASX:PLT)

12.8%

120.1%

EHang Holdings (NasdaqGM:EH)

31.4%

79.6%

Brightstar Resources (ASX:BTR)

16.2%

84.5%

Elliptic Laboratories (OB:ELABS)

26.8%

111.4%

Findi (ASX:FND)

34.8%

112.9%

Click here to see the full list of 1498 stocks from our Fast Growing Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

Técnicas Reunidas

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Técnicas Reunidas, S.A. is an engineering and construction company that specializes in designing and managing industrial plant projects globally, with a market cap of approximately €1.01 billion.

Operations: The company's revenue is primarily derived from the Natural Gas segment at €2.55 billion, followed by Refining at €669.71 million, Petrochemical at €655.17 million, and Low Carbon Technologies contributing €111.52 million.

Insider Ownership: 11.5%

Earnings Growth Forecast: 20.7% p.a.

Técnicas Reunidas shows promising growth potential with earnings expected to grow significantly at 20.7% annually, outpacing the Spanish market. Despite a volatile share price, the company has seen a 55.9% increase in earnings over the past year and is trading below its estimated fair value. Recent results indicate stable sales performance, with net income rising to €65.7 million for the nine months ending September 2024, despite slightly lower revenues compared to last year.

BME:TRE Earnings and Revenue Growth as at Jan 2025
BME:TRE Earnings and Revenue Growth as at Jan 2025

Innovita Biological Technology

Simply Wall St Growth Rating: ★★★★★★

Overview: Innovita Biological Technology Co., Ltd. focuses on the R&D, manufacturing, marketing, and sales of POCT rapid diagnostic products and has a market cap of CN¥4.90 billion.